---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-029998"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:30:01.034825+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Roivant Q1 loss widens to $0.33/share; completes $1.5B buyback, initiates new $500M program

## Summary
- GAAP loss from continuing ops $273.9M ($0.33/share) vs income $31.6M ($0.01) YoY; revenue $2.2M down from $8.0M.
- Non-GAAP loss from continuing ops $170.1M vs $107.1M YoY; R&D spend up $32.4M to $152.9M.
- Completed $1.5B share repurchase program; board approved new $500M buyback in June 2025.
- Cash, equivalents, restricted cash and marketable securities $4.5B; shares outstanding reduced >15% from Mar 2024.
- Brepocitinib VALOR DM Phase 3 topline data H2 2025 (LPLV July); IMVT-1402 registrational trials started in GD, SjD June.

## SEC filing metadata
- accession: 0001140361-25-029998
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125029998/0001140361-25-029998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125029998/ef20053385_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-029998
- JSON: https://secwatch.observer/filing/0001140361-25-029998.json
- Plain text: https://secwatch.observer/filing/0001140361-25-029998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.